A review on biosketch of anti- malarial drug

Vaishnavi P. Lande[1] , Mr. Harishkumar Rathod[2], Dr . Swati P. Deshmukh[3]

[1]Shraddha institute of pharmacy Kondala Zambre , Washim-444505
[2]Assistant Professor of Shraddha institute of pharmacy , Kondala Zambre Washim-444505
[3]Principal of Shraddha institute of pharmacy Kondala Zambre, Washim-444505

Abstract :

Malaria continues to affect public health and economic growth in many regions of the world. The number of infections continues to rise and is associated with increased mortality, despite basic science and public health efforts. Drug therapy remains the mainstay of treatment and prevention of this disease. Plasmodium has a complex life cycle involving an arthropod vector and distinct stages within the human host. Each parasite stage plays a unique role in transmission, disease, and latency. These different stages may vary in their response to the various antimalarial compounds. This article will review antimalarial therapies and drug resistance in the context of the parasites' biology.

For control malaria are used & elimination of rantimalarial drugs. Because of development of artemisinin the combination therpies in burden based decrease of malaria. There is potential spread of artemisinin. Resistant Urgent parasites in Asia have raised Concerns Due to this threat the TCEMRS. International Centers of Excellence for malaria Research ane studying the mechanism & underlying doug resistance Research activities. Are taken at multiple sentinel sites of the global ICEMR network For ex vivo/ in vitro assays to measure droug ceptibilities of parasites isolates & charcterisation of resistance – megreting panasite polymerphisms. From this we antimalarial review Worldwild drug resistance concerns Summarize research activitie of the ICEMRS related to droug resistance

Self-medication for malaria is very common in Sub-Saharan Africa where this parasitosis is endemic. In order to determine the extent, characteristics and factors associated with this practice in medical area in the city of Lubumbashi, a cross-sectional descriptive study was carried out by direct interview from January 2018 to June 2018, in the internal medicine departments of 10 General Referral Hospital (GRH). Five thousand one hundred and thirty- four patients were consulted among them, 96.6% (average age 38.7 ± 8 years; average income: 100+ 12 USD; gender male/female ratio: 0.86) practice self-medication with antimalarials. They used it for the first time at an average age of 13-17 years. Quinine (36.4%) and Carica papaya (0.4%) are the most used remedies in conventional and non-conventional medicine, respectively. Several risks are incurred during this practice when the most cited are worsening side effects (53%), incomplete treatment (37%) and appearance to health sciences (37%). Age (17-35 and > 65 years old), low income (50-150 USD), membership in a health sector and the claim to know antimalarial drugs, predispose patients to self-medication. There is an urgent need to regulate this practice to avoid its harmful consequences. Area study Lubumbashi (DR Congo) Descriptive study by interview (n: 5134) in 10 General Referral Hospital Prevalence of self-

Key Words,: Anti-Malarial , Artemisinin , Quinine , Parasitosisi.

INTRODUCTION.

These are drugs used for prophylaxis, treatment and prevention of relapses of malaria Malaria. Caused by 4 species of the protozoal parasite Plasmodium, is endemic in most parts of India and other tropical countries. It is one of the major health problems. As per latest WHO estimates (2011) between 149-274 (median 216) million clinical cases and -0.655 million deaths occur globally due to malaria each year, 90% of which are in Africa. This amounts to one malaria death every minute. In India the National Malaria Eradication Programme (NMEP), started in 1958, achieved near complete disappearance of the disease in 1960s (from 75 million cases in 1950s to 0.1 million cases in 1960s) However, due to the development of insecticide resistance among mosquitoes and other factors, it staged a comeback in the mid 1970s (6.47 million cases in 1976), and continues to prevail in endemic subendemic proportions, so that 80% indian population lives in malaria risk areas Conceding that eradication of malaria is not possible, NMEP was renamed National Antimalaria Programme (NAMP), which now is 'National vector borne diseases control programme (NVBDCP) with a wider disease coverage. For the year 2010, the NVBDCP has reported 1.49 million slide proven malaria cases in India, out of which 0.78 million (52%) were falciparum malaria with 767 recorded deaths. The WHO estimates that actual number of malaria cases in India is much higher and an expert committee has estimated that about 40,000 malaria deaths occur annually. The bark of Cinchona tree, growing in Peru, was introduced in Europe in the early 17th century as a cure for fevers Later it was realized to be a specific remedy for malana. Quinine, isolated from Cinchona bark in 1820, replaced the crude preparation and continued to be the major antimalarial drug till 1942. The world's supply of Cinchona bark for producing quinine was met by Java and neighbouring countries. This was cut off from the Germans during World War I and from the Allies during World War II Due to enormous military importance of malaria and its treatment, intense activity was initiated for the development of antimalarial drugs. Mepacrine was produced in Germany in 1926 and extensively field tested by the Allies during World War II Chloroquine was produced in USA soon after as a less toxic alternative to mepacrine. It had already been synthesized and used by Germans in 1934 as 'Resochin Proguanil was introduced in 1945 by the British as a well tolerated clinical curative. None of the above drugs were found to be capable of preventing relapses in vivax malaria. Pamaquine was the first 8-aminoquinoline to be tested in Germany in the 1920s. However, no attention was paid to it because of its poor schizontocide action. This class of drugs was retested during World War II as radical curative and Primaquine emerged as the most desirable drug Pyrimethamine was produced in 1951 under a planned post-war research programme for antimalarial drugs. Subsequently, chloroqume resistance emerged in P falciparum and several drugs were developed to combat it, the important ones are Mefloquine Lumefantrine. Atovaquone, Pyronaridine, etc.

However, the most significant advance is the Chinese herb derived fast acting Artemisinin compounds, the latest one of which is a synthetic derivative Arterolane developed in Indias a synthetic derivative Arterolane developed in India Some varieties of the malaria parasite, which typically cause milder form of the disease, can perisits for years can cause a relpases Scientists around the world are trying to develop a safe and effective vaccine of malaria. As of yet, however, there is still no malaria vaccine approved for human use. Malaria is caused by four species of a one-cell protozoan of the Plasmodium genus .

TYPES OF MALARIA

uncomplicated Malaria

The most common symtoms of uncomplicated malana are :

- Fever and chills
- Headaches
- Nausea and vomiting
- General weekness and body aches.

Other signs and symtoms may include
Sweating Chest
abdominal pain
Cough
Complicated or Severe Malaria:
This occurs when malaria affects different body systems. The most common symptoms of complicated malaria are:
Severe anemia (due to destruction of red blood cells):
Cerebral malaria-seizures, unconsciousness, abnormal behavior, or confusion. Cardiovascular collapse. Low blood sugar (in pregnant women after treatment with quinone. In most cases, malaria deaths are related to one or more serious complications, including.
Cerebral malaria:
If parasite-filled blood cells block small blood vessels to brain (cerebral malaria), swelling of brain or brain damage may occur. Cerebral malaria may cause seizures and coma Into the ble blood cells. 1 On to the n this point in them to the e Enter Browser o 4.5 LIFE CYCLE
Breathing problems:
Accumulated fluid in lungs (pulmonary edema) can make it difficultto breathe. Organ failure: Malaria can cause kidneys or liver to fail, or spleen to rupture. Any of these conditions can be life-threatening.
Anemia:
Malaria damages red blood cells, which can result in anemia. . Low blood sugar. Severe forms of malaria itself can cause low blood sugar (hypoglycemia), as can quinine one of the most common medications used to combat malaria. Very low blood sugar can result in coma or death .

PARSITE TRANSMISSION CYCLE :

If any person gets mosquito bites, then it can trasmit malaria parasites to that particular. Person. In the liver:
As the parasites enter in the body of that person. Who is suffering for malaria, they travel to liver Where as after some types it can lie dormant. For many year.
Into blood stream:
At this stage when parasites get mature, the y are remove for liver and infect RBC. [Red Dhood d celle In this stage people typically malaria Symtom 3: such as haused, vometing fever ete On the next person. When the unitected mosquito bites to the another person who is infected one of this point in The que After this person became infected. With malaria parasits and also spared to the another person, when mosquito get bites



Life of Plasmodium

LIFE CYCLE OF MALERIA

1. Malaria infection begins when an infected female Anopheles mosquito bites a person.
2. The sporozoites pass quickly into the human liver. Injecting Plasmodium parasites, in the form of sporozoites, into the bloodstream.
3. The sporozoites multiply asexually in the no symptoms. Liver cells in vesicles.
4. In an animal model, the parasites, in the form of merozoites, are released from the liver cells in vesicles.
5. Merozoites pass through the heart and arrive in the lungs, where they settle within lung capillaries. 6.
The vesicles eventually ruptured and released the merozoites enter in the blood phase of their development.
7. In the bloodstream, the merozoites invade red blood cells (erythrocytes) and multiply again until the cells burst.
8. Then they invade more erythrocytes. This cycle is repeated, causing fever each time parasites break free and invade blood cells.
9. Some of the infected blood cells leave the cycle of asexual multiplication. Instead of replicating, the merozoites in these cells develop into sexual forms of the parasite, called gametocytes that circulate in the blood stream.
10. When a mosquito bites an infected human, it ingests the gametocytes, which develop further into mature sex cells called gametes.
11. The fertilized female gametes develop into actively moving cokinetes that burrow through the mosquito's mid-gut wall and form oocysts on the exterior surface.
12. Inside the oocyst, thousands of active sporozoites develop. The oocyst eventually bursts, releasing sporozoites into the body cavity that travel to the mosquito's salivary glands.
13. The cycle of human infection begins again when the mosquito bites an**other person.**



Life of Malaria

CLASSIFICATIONS

14-Aminoquinolines Piperaquine.	Chloroquine (CQ) Amodiaquine (AQ)
2. Quinoline-methanol	Mefloqunine
3. Cinchona alkaloid	Quinine Qunidine
4. Biguanide.	Proguanil (Chlorogunide)
5. Diaminopyrimidine	Pyrimethamine
6. 8-Aminoquinoline	Primaquinine Tafenoquine
7. Sulfonamides Sulfadoxine and sulfone	Sulfamethamine Opyrazine Dapsone
8. Antibiotics	Tetracycline Doxycycline Clindamycin
9. Sesquiterpine Arterolane	Artesunate Lactone Arteether Artemether
10. Amino alcohols.	Halfantrine Lumefentrine
11. Naphthyridine	Pyronaridine
12. Naphthoquinone	Atovaquon

Machanism of Chloroquinie.

In acidic vacuolu Plasmodia is derived nutrition by digesting haemoglobin. Chloroquine is actively concentrated by intravrythre – cytic plasmodia & High conc. Is found in inflend RIS than non-infected ones. By intereferring in the acidic vecuoles of parasite I because of Basie nature, it raisi Vacuolar pil of I leads to degradation of Harmoglobin by parasitic lysosomes Polymerization of toxic haeme generated from digestion of haemoglobin to nonfonce parasite haemoroin is inhibit by eq-haeme complex Haeme (its complex damages the plasmodial membranes. Other antimalarials like quinine, mefloquine etc. appears to act analogous. P vivax has been slow developing but P falciparum acquired resistance & it become prevalent in India, South rast area, chira, Africa South Americe. Some drugs are revistance to Sulfapyrimethamin + proguanit she P. falciparum givy- malaria o more severe forms of with mortality.

Chloroquine -resistance among P. spread in India. Falciparum are from so The largest && failurys. Northesten part of India P falaparum are rusistant to CJ about 24-831- 8 rusistant P.F to most parts of Andia with Northeast, Orissa, Karnataka in NVBDCP has switched over Act first line treatment PP cases country wide. Parasite to accumulate CQ decreased ability of P. falciparum resistance An efflux 4. Chloroquine

Chloroquine is a 4-aminoquinoline." It is almost completely absorbed when taken orally, though peak plasma concentrations can vary. This drug is inex- pensive, well tolerated, and available intramuscularly (IM) and intravenously (IV). Chloroquine is metabo- lized in the liver, mainly to monodesethylchloro- quine. This drug is an amphiphilic weak base and will accumulate in the parasite food vacuole because of a pH gradient. The food vacuole is the site of par- asite metabolism of its main food source, hemoglo- bin. The parasite detoxifies hemoglobin metabolites, and chloroquine interference with this process results in parasite death. The precise molecular mecha- nism of action remains unclear. Potential targets include inhibition of parasite endocytosis or inter- ference of other enzyme pathways involving the vac- uolar phospholipases or hemoglobin proteases." The indication for chloroquine as a chemopro- phylaxis and treatment is markedly limited because of widespread drug resistance in P falciparum. Resistance in East Africa was reported in 1978, and over a period of 10 years, resistance spread through- out the continent. Analysis of a genetic cross

of achloroquine drug-sensitive and drug-resistant strain resulted in the identification of multiple mutations in the parasite pfcrt gene, which is associated with chloroquine resistance.42.43 Pfcrt encodes a protein located in the food vacuole. The normal function of this protein remains unknown, but it may mediate the pH gradient of the food vacuole or transport amino acids or small peptides. Some parasites con- tain the chloroquine resistance-associated pfcrt muta- tions yet do not display in vivo or in vitro resistance, suggesting that additional mutations in other genes are necessary to confer a resistant phenotype.43,45-48 When Malawi discontinued use of chloroquine in 1993 because of a high prevalence of chloroquine resistance, the prevalence of the pfcrt mutations dropped significantly over the following years, with an increase in parasite in vitro chloroquine sensi- tivity, raising the possibility of recycling drugs. 49-52 Chloroquine-resistant strains have a higher food vac- uole pH and accumulate less drug in the vacuole.53 Interestingly, chloroquine resistance can be reversed by verapamil, reminiscent of a similar phenomenon found in multiple drug-resistant mammalian tumor cells.54 This phenotype led to the identification of pfmdr1, which encodes a p-glycoprotein also located.



MECHANISM OF ACTION OF CHLOROQUINIE

Pharmacokinetics

Oral absorption of CQ is excellent. About 50% gets bound in the plasma. It has high affinity for melanin and nulear chromatin gets tightly bound to these tissue constituents and is concentrated in liver, spleen, kidney, lungs (several hundred-fold), skin, leucocytes and some other tissues. Its selective accumulation in retina is responsible for the ocular toxicity seen with prolonged use. Chloroquine is partly metabolized by liver and slowly excreted in urine. The early plasma t½ varies from 3-10 days. Because of tight tissue binding, small amounts persist in the body with a terminal 1% of 1-2 months.

USES

1. CQ causes rapid fever clearance and disappearance of parasitaemia in patients of malaria caused by all P.ovale and P.malariae, most P.vivax and some P.falciparum that are still sensitive. It is the drug of choice for clinical cure of vivax, ovale and malariae malaria. However, its use for P. falciparum is restricted few areas that still have susceptible P.f.. but not in India. It is no longer used as a suppressive prophylactic in India, and such use is made only in vivax predominant countries or in those which have CQ-sensitive P.f. THERAPY FOR ANTY-MALERIAL DRUG
2. Extraintestinal amoebiasis (Ch. 60).
3. Rheumatoid arthritis (Ch. 15)
. 4. Discoid lupus erythematosus very effective; less valuable in systemic LE
. 5. Lepra reaction (see p. 786
6. Photogenic reactions.

7. Infectious mononucleosis: affords symptomatic relief.

TREATMENT OF MALARIA

There are four possible sites for drug therapy. 1. Kill the sporozoites injected by the mosquito and/or prevent the sporozoites from 2. Kill the schizonts residing in hepatocytes and/or prevent them from becoming entering the liver merozoites 3. Kill the merozoites in the blood and/or prevent them from developing into gametocytes 4 Kill the gametocytes before they can enter the mosquito and reproduce into zygotes The main focus of drug therapy at this site should be on the male gametocytes. This would block the female gametocytes from mating. Anti-malarial drugs are good examples of anti-infective agents with poor selective toxicity. Contrast them with the antibiotics tetracyclines, chloramphenicol and aminoglycosides act against bacterial ribosomes, but not mammalian ones Penicillins and cyclosporines inhibit bacterial cell wall crosslinking, and mammals have cell membranes, not cell walls. The fluoroquinolones inhibit bacterial gyrase, but not mammalian topoisomerases. The biochemistry of Plasmodium spp is similar to that of mammals, making it difficult to design drugs that will not affect the patient adversely. Indeed, some have indications beyond treating and preventing malaria.

CONTRAINDICATIONS

After taking chloroquine patients will experience gastrointestinal. Upset, headache, blupped vision, and insomania QT interval prolongtion has rarely shown Patients with of GI C previous history. Disorders, conduction absnormalities or patients taking QT-prolonging drugs requines caution. Hydroxychloroquine and chloroquine dougs have been reported to cause psoriatic exacerbations side effect of hydno- exychloroquine are similar to chloroquine Hemolytic anemia in patient with GCPD deficiency is caused by Primaquine GI distrubances, such nausea common abdominal pain, and vomiting is a side effect of prolmaquine Common side effects of artovaquone proguanil are. Abdominal headache & pain nausea, vomiting increased serum framsaminases Atovaquene - phoquanil may also enhance may also the anticoagulant enhance the anticoagulant effect of warfarin Patients taking both drugs should be monitored closely bleeding episodes Doxycycline & tetracycline are usually well tolerated, but So me GT upset can be Seen & less commonly ultraviolet photosensitivity Patients should apply for increased sunscreen Clindamycin most commonly causes – GI distrubance most notably diarrhea & is the most associated. Common antibiotic with C difficile infection 5 post treatment. GT upset light headedness, headache, difficulty concentrating, mood swings, & strange dreams are side effects of Mefloquine can cause neuropsychiatric effects even after discontinuation Severe neutropsychiatric Involve reaction Seizures Suicidal ideation & psychosis

CONCLUSION

Plasmodium infections pose a tremendous burden on global health. This is in contrast to the limitedarmamentarium of effective antimalarial therapies. The parasites' diverse biology at each stage and ability to select for drug-resistant strains presents a great chal- lenge to therapeutic development. The understanding of parasite biology, transmission, and drug resistance will provide new options for effective therapy and reduce transmission of this often deadly disease.

REFRENCE :

1. K.D. Tripathi "Essential of medical pharmacology" 7th edition,2013 Japess Brother medical publisher (P) LLD New Delhi.
2. TEXTBOOK of Medicinal Chemistry III "1" edition Dr. SANJAY G. WALODE, Dr CHANDAN R.S. Dr. (Mrs) ALPANA JASNANI.
3. Wiseman V, Onwujekwe O. Matovu F. Mutabingwa TK, Whitty CJ. Differences in willingness to pay for artemisinin-based combinations or monotherapy: experiences from the United Republic of Tanzania. Bull World Health Organ. 2005;83:845-852.
4. Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther. 1998;79:55-87.
5. Yayon A, Cabantchik ZI, Ginsburg H. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 1984;3:2695-2700.
6. Ginsburg H, Famin O, Zhang J, Krugliak M. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem Pharmacol. 1998;56:1305-1313.
7. .Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance. Int J Parasitol. 1997;27:231-240.
8. Hoppe HC, van Schalkwyk DA, Wiehart UI, Meredith SA, Egan J, Weber BW. Antimalarial quinolines and artemisinin inhibit endo- cytosis in Plasmodium falciparum. Antimicrob Agents Chemother. 2004;48:2370-2378.
9. Olliaro P. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol Ther. 2001;89:207-219.
10. .Sullivan DJ. Theories on malarial pigment formation and quinoline action. Int J Parasitol. 2002;32:1645-1653.
11. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. fal- ciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000; 6:861-871.
12. Djimde A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001; 344:257-263.
13. Cooper RA, Hartwig CL, Ferdig MT. pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective. Acta Trop. 2005;94:170-180.
14. Dorsey G, Kamya MR, Singh A, Rosenthal PJ. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clin- ical response to chloroquine in Kampala, Uganda. J Infect Dis. 2001;183:1417-1420.
15. .Daily JP, Roberts C, Thomas SM, et al. Prevalence of Plasmodium falciparum pfert polymorphisms a in vitro chloro- quine sensitivity in Senegal. Parasitology, 2003;126:401-405.

16. .Brockman A, Price RN, van Vugt M, et al. Plasmodium falci- parum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate- mefloquine. Trans R Soc Trop Med Hyg. 2000;94:537-544.
17. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9-17.
18. White NJ. Clinical pharmacokinetics and pharmacodynam- ics of artemisinin and derivatives. Trans R Soc Trop Med Hyg. 1994;88(suppl 1):S41-S43.
19. A meta-analysis using individual patient data of trials com- paring artemether with quinine in the treatment of severe falci-parum malaria. Trans R Soc Trop Med Hyg. 2001;95:637-650.
20. .Newton PN, Angus BJ, Chierakul W, et al. Randomized com- parison of artesunate and quinine in the treatment of severe falci- parum malaria. Clin Infect Dis. 2003;37:7-16.
21. Kumar N, Zheng H. Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falci-parum. Parasitol Res. 1990;76:214-218.
22. . Targett G, Drakeley C, Jawara M, et al. Artesunate redu ces but does not prevent posttreatment transmission of Plasmodium falci- parum to Anopheles gambiae. J Infect Dis. 2001;183:1254-1259.
23. World Health Organization. Antimalarial Drug Combination Therapy: Report of a WHO Technical Consultation. Geneva, Switzerland: World Health Organization; 2001.
24. Omari AA, Preston C, Garner P. Artemether-lumefantrine for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2002;CD003125.
25. Jambou R, Legrand E, Niang M, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point muta- tions of the SERCA-type PfATPase6. Lancet. 2005;366:1960-1963.
26. Hallett RL, Sutherland CJ, Alexander N, et al. Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother. 2004;48:3940-3943.
27. Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg. 1997;56:621-626.
28. Ruebush TK II, Zegarra J, Cairo J, et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am J Trop Med Hyg. 2003;69: 548-552.